Why SRTA rose on Nov 4
Up 18% on Nov 4.
- Our sources do not explain the move yet.
- The S&P 500 rose 1.7% that day.
SRTA's Quality Score fell 3 points on Fri, Nov 13, to 5. The insider buying headlines count for less as they age.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 18% on Nov 4.
| Holding it back | A $25M loss after a $40M profit a year earlier |
| Latest filing | 8-K, Nov 3 |
After its last 4 reports it closed +5.4% on average, higher 4 of 4 times.
Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
SRTA is #8 of 15 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 8 |
Expected to report Tue Mar 2, before the open (in 106 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $74.1M, 50% more than a year ago; a loss of $0.09 a share.
“Total revenue increased 50.3% to $74.1 million in Q3 2026 versus $49.3 million in the prior year period driven by Clinical acquisitions partially offset by Logistics.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Logistics | $44.9M | $48.2M | $46.5M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)
| Measure | Figure |
|---|---|
| Revenue | $285.00 |
“Gross margin increased 110 basis points to 22.7% in Q3 2026 versus 21.6% in the prior year period driven primarily by the positive mix impact of our larger Clinical segment, which also saw margin expansion versus 2025, partially offset by a decline in Logistics gross margin.”
From its results filing (SEC filing · Nov 3)
Sales grew 11% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 4.8% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +8.8% | +3.7% | +41.4% |
| Aug 4, 2026 | -2.7% | +0.4% | +7.0% |
| May 6, 2026 | +13.9% | +10.6% | +13.5% |
Sales grew in two of the last three years, to $197M in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 58.0, MACD above signal, above both averages. Not scored.
One insider bought $10K across 1 filing, and 5 insiders sold $450K across 5 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: SRTA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
“In Air and Ground Logistics, we compete primarily with Part 135 jet operators and a limited number of asset-light logistics businesses.”
SRTA scores 5 today, which Breakaway calls Below Average. It is #8 of 15 in Transportation Services by Quality Score, with 2 of 14 chart checks firing. Up 18% on Nov 4. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SRTA scores 5 today, which Breakaway calls Below Average (0 to 5). That is #8 of 15 in Transportation Services by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SRTA's 5.
One insider bought $10K across 1 filing, and 5 insiders sold $450K across 5 filings, in the last 6 months. The newest is Andrew Lauck, Director, who bought $10K on Nov 5. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.